Rentokil Initial Plc. ADR (RTO) concluded trading on Wednesday at a closing price of $24.11, with 0.47 million shares of worth about $11.44 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -21.00% during that period and on January 08, 2025 the price saw a loss of about -1.71%. Currently the company’s common shares owned by public are about 502.31M shares, out of which, 502.17M shares are available for trading.
Stock saw a price change of -4.78% in past 5 days and over the past one month there was a price change of -9.02%. Year-to-date (YTD), RTO shares are showing a performance of -4.78% which decreased to -10.10% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $22.40 but also hit the highest price of $34.07 during that period. The average intraday trading volume for Rentokil Initial Plc. ADR shares is 760.86K. The stock is currently trading -5.31% below its 20-day simple moving average (SMA20), while that difference is down -6.40% for SMA50 and it goes to -12.46% lower than SMA200.
Rentokil Initial Plc. ADR (NYSE: RTO) currently have 502.31M outstanding shares and institutions hold larger chunk of about 12.85% of that.
The stock has a current market capitalization of $12.11B and its 3Y-monthly beta is at 1.08. PE ratio of stock for trailing 12 months is 24.71, while it has posted earnings per share of $0.98 in the same period. Its PEG reads 9.34 and has Quick Ratio of 0.96 while making debt-to-equity ratio of 1.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RTO, volatility over the week remained 1.39% while standing at 1.62% over the month.
Analysts are in expectations that Rentokil Initial Plc. ADR (RTO) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0.86 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -9.04% while it is estimated to increase by 4.95% in next year.
On April 23, 2024, JP Morgan Resumed their recommendations, while on January 24, 2024, BofA Securities Downgrade their ratings for the stock with a price target of $29. Stock get a Neutral rating from Exane BNP Paribas on March 22, 2023.
